ANIXA BIOSCIENCES, INC. (ANIX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-07-31..
Operating margin
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -10.98M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 4.83M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-07-31 | $-10.98M | (m) | (m) | $4.83M | (m) | (m) |
| 2026-04-30 | $-10.68M | (m) | (m) | $4.56M | (m) | (m) |
| 2026-01-31 | $-11.03M | (m) | (m) | $4.62M | (m) | (m) |
| 2025-10-31 | $-11.70M | (m) | (m) | $5.07M | (m) | (m) |
| 2025-07-31 | $-11.99M | (m) | (m) | $5.41M | (m) | (m) |
| 2025-04-30 | $-13.14M | (m) | (m) | $6.28M | (m) | (m) |
| 2025-01-31 | $-13.61M | (m) | (m) | $6.60M | (m) | (m) |
| 2024-10-31 | $-13.83M | $210.00K | (m) | $6.40M | (m) | -6586.19% |
| 2024-07-31 | $-13.72M | (m) | (m) | $6.54M | (m) | (m) |
| 2024-04-30 | $-12.97M | $210.00K | (m) | $5.70M | (m) | -6176.67% |
| 2024-01-31 | $-12.06M | (m) | (m) | $5.05M | (m) | (m) |
| 2023-10-31 | $-11.01M | $210.00K | (m) | $4.77M | (m) | -5243.33% |
| 2023-07-31 | $-11.57M | (m) | (m) | $4.84M | (m) | (m) |
| 2023-04-30 | $-11.52M | (m) | (m) | $5.20M | (m) | (m) |
| 2023-01-31 | $-12.55M | (m) | (m) | $5.93M | (m) | (m) |
| 2022-10-31 | $-13.88M | (m) | (m) | $6.70M | (m) | (m) |
| 2022-07-31 | $-14.34M | (m) | (m) | $7.19M | (m) | (m) |
| 2022-04-30 | $-15.93M | $512.50K | (m) | $7.91M | (m) | -3109.21% |
| 2022-01-31 | $-14.78M | $512.50K | (m) | $7.20M | (m) | -2884.43% |
| 2021-10-31 | $-13.14M | $512.50K | (m) | $6.19M | (m) | -2563.06% |
| 2021-07-31 | $-11.30M | (m) | (m) | $4.42M | (m) | (m) |
| 2021-04-30 | $-9.35M | (m) | (m) | $3.51M | (m) | (m) |
| 2021-01-31 | $-9.58M | (m) | (m) | $3.72M | (m) | (m) |
| 2020-10-31 | $-9.98M | (m) | (m) | $4.38M | (m) | (m) |
| 2020-07-31 | $-9.86M | (m) | (m) | $4.84M | (m) | (m) |
| 2020-04-30 | $-9.61M | (m) | (m) | $4.68M | $4.90M | (m) |
| 2020-01-31 | $-9.54M | (m) | (m) | $4.72M | $4.74M | (m) |
| 2019-10-31 | $-11.89M | $250.00K | (m) | $5.47M | $5.66M | -4756.00% |
| 2019-07-31 | $-15.17M | $250.00K | (m) | $7.04M | $6.71M | -6067.64% |
| 2019-04-30 | $-18.59M | $612.50K | (m) | $8.89M | $8.36M | -3035.18% |
| 2019-01-31 | $-17.40M | (m) | (m) | $8.28M | $7.99M | (m) |
| 2018-10-31 | $-14.29M | $1.11M | (m) | $6.81M | $6.91M | -1284.41% |
| 2018-07-31 | $-10.62M | $1.11M | (m) | $4.73M | $5.95M | -954.52% |
| 2018-04-30 | $-6.74M | (m) | (m) | $2.15M | $4.75M | (m) |
| 2018-01-31 | $-6.56M | (m) | (m) | $1.92M | $4.54M | (m) |
| 2017-10-31 | $-6.08M | $362.50K | (m) | $1.60M | $4.41M | -1676.02% |
| 2017-07-31 | $-5.25M | $562.50K | (m) | $1.66M | $3.61M | -933.55% |
| 2017-04-30 | $-4.50M | (m) | (m) | $1.59M | $2.74M | (m) |
| 2017-01-31 | $-4.43M | (m) | (m) | $1.55M | $2.70M | (m) |
| 2016-10-31 | $-4.51M | $300.00K | (m) | $1.56M | $2.71M | -1503.00% |
| 2016-07-31 | $-4.77M | $100.00K | (m) | (m) | $4.38M | -4773.24% |
| 2016-04-30 | $-5.29M | (m) | (m) | (m) | $4.88M | (m) |
| 2016-01-31 | $-6.27M | (m) | (m) | (m) | $5.78M | (m) |
| 2015-10-31 | $-944.76K | $9.26M | (m) | (m) | $6.23M | -10.21% |
| 2015-07-31 | $-1.33M | $10.63M | (m) | (m) | $6.75M | -12.53% |
| 2015-04-30 | $-565.00 | $11.72M | (m) | (m) | $6.43M | -0.00% |
| 2015-01-31 | $777.40K | (m) | (m) | (m) | $6.32M | (m) |
| 2014-10-31 | $-5.04M | $3.67M | (m) | (m) | $6.41M | -137.54% |
| 2014-07-31 | $-5.25M | $2.68M | (m) | (m) | $6.68M | -196.15% |
| 2014-04-30 | $-7.31M | (m) | (m) | (m) | $7.78M | (m) |
| 2014-01-31 | $-7.81M | (m) | (m) | (m) | $7.85M | (m) |
| 2013-10-31 | $-7.92M | $388.85K | (m) | (m) | $7.99M | -2036.17% |
| 2013-07-31 | $-7.87M | $2.48K | (m) | (m) | $7.34M | -317265.85% |
| 2013-04-30 | $-6.29M | $251.95K | (m) | (m) | $5.56M | -2497.69% |
| 2013-01-31 | $-5.32M | $500.02K | (m) | (m) | $4.23M | -1063.98% |
| 2012-10-31 | $-4.13M | $947.09K | (m) | $2.21M | $2.87M | -436.56% |
| 2012-07-31 | $-3.42M | $1.40M | (m) | $2.45M | $2.36M | -244.73% |
| 2012-04-30 | $-3.98M | $1.60M | (m) | $2.87M | $2.70M | -249.28% |
| 2012-01-31 | $-4.39M | $1.44M | (m) | $3.00M | $2.80M | -305.79% |
| 2011-10-31 | $-5.03M | $1.00M | (m) | $3.12M | $2.87M | -501.23% |
| 2011-07-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-01-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-10-31 | $-5.25M | $730.67K | (m) | $3.01M | $2.89M | -718.27% |
| 2010-07-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |